Management of Ischaemic Heart Disease in Diabetic Patients - Is there a Role for Cardiac Metabolic Agents?

References

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Moreno PR, Murcia AM, Palacios IF et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180–84
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin dependent diabetes mellitus – a special reference to statins. J Diabetes Complic 2001;15:211–26
   PubMed Web of Science ®Google Scholar
• Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and no-Q-wave myocardial infarction. Circulation 2000;102:1014–9
   PubMed Web of Science ®Google Scholar
• Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25–33
   PubMed Web of Science ®Google Scholar
• Barrett EJ, Schwartz RG, Francis CK et al. Regulation by insulin of myocardial glucose and fatty acid metabolism in the conscious dog. J Clin Invest 1984;74:1073–1079
   PubMed Web of Science ®Google Scholar
• Gamble J, Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischaemic hearts from diabetic rats. Biochim Biophys Acta 1994;1225:191–199
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis 1996;7:116–123
   PubMed Web of Science ®Google Scholar
• Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rat. Biochim Biophys Acta 1989;1006:97–103
   PubMed Web of Science ®Google Scholar
• Avogaro A, Nosadini R, Doria A et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol 1990;258:E606–E618
   PubMed Web of Science ®Google Scholar
• Hall JL, Stanley WC, Lopaschuk GD et al. Impaired pyruvate oxidation but not glucose uptake in diabetic pig heart during dobutamine stress. Am J Physiol 1996;271:H2320–H2329
   PubMed Web of Science ®Google Scholar
• Yeaman SJ. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem J 1989;257:625–32
   PubMed Web of Science ®Google Scholar
• Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacologic interventions. Cardiovasc Res 1997;33:243–57
   PubMed Web of Science ®Google Scholar
• Shapiro LM, Howat AP, Calter MN. Left ventricular function in diabetes mellitus. Methodology and prevalence and spectrum of abnormalities. Br Heart J 1991;45:122–8
   Google Scholar
• Bellodi G, Manicardi V, Malavasi V et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989;64:885–8
   PubMed Web of Science ®Google Scholar
• Paulson DJ, Shug AL, Jurak R, Schmidt M. The role of altered lipid metabolism in the cardiac dysfunction associated with diabetes. In: The Diabetic Heart (Eds Nagaro M, Dhalla NS). Raven Press, New York, pp. 395–407, 1991
   Google Scholar
• Reaven GM. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374–81
   PubMed Web of Science ®Google Scholar
• Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695–701
   PubMed Web of Science ®Google Scholar
• Bierman EL. Atherogenesis in diabetes. Atheroscler Thromb 1992;12:647–56
   PubMed Web of Science ®Google Scholar
• Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695–701
   PubMed Web of Science ®Google Scholar
• Niskanen L, Turpeinen A, Penttila I, Uusitupa MIJ. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998;21:1861–9
   PubMed Web of Science ®Google Scholar
• Koskinen P, Manttari M, Manninen V, Huttunene JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–25
   PubMed Web of Science ®Google Scholar
• Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997;20:469–71
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic subjects and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998;98:2513–9
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–62
   Google Scholar
• Sawicki PT, Berger M. Pharmacological treatment of diabetic patients with cardiovascular complications. J Int Med 1998;243:181–9
   PubMed Web of Science ®Google Scholar
• Reynolds JEF (Ed). Martindale: The Extrapharmacopoeia. Royal Pharmaceutical Press, London, pp. 830–31, 1996
   Google Scholar
• Byington PR. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997;350:1075–6
   PubMed Web of Science ®Google Scholar
• Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 1998;351:216–7
   PubMed Web of Science ®Google Scholar
• Julien J. Cardiac complications in non-insulin-dependent diabetes mellitus. J Diabetes Complic 1997;11:123–30
   PubMed Web of Science ®Google Scholar
• The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761–9
   PubMed Web of Science ®Google Scholar
• Henderson RA, Pocock SJ, Sharp SJ et al. for the Randomized Intervention Treatment of Angina (RITA-1) Trial Participants. Long-term results of RITA-1 trial: clinical and cost comparison of coronary angioplasty and coronary artery bypass grafting. Lancet 1998;352: 1419–25
   PubMed Web of Science ®Google Scholar
• King III SB, Lembo NJ, Weintraub WS et al. for the Emory Angioplasty versus Surgery Trial (EAST). A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 1994;331:1044–50
   PubMed Web of Science ®Google Scholar
• Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866–73
   PubMed Web of Science ®Google Scholar
• The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956–61
   PubMed Web of Science ®Google Scholar
• Kleiman NS, Lincoff AM, Kereiakes DJ et al. for the EPILOG Investigators. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction in a multicenter trial. Circulation 1998;97:1912–20
   PubMed Web of Science ®Google Scholar
• The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87–92
   PubMed Web of Science ®Google Scholar
• Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995;123:358–67
   PubMed Web of Science ®Google Scholar
• Malmberg K, Ryden L, Hamsten A et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. Eur Heart J 1996;17:1337–44
   PubMed Web of Science ®Google Scholar
• Diaz R, Paolasso EC, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998;98:2227–34
   PubMed Web of Science ®Google Scholar
• Fath-Ordoubadi F, Beatt KJ. Glucose–insulin–potassium (GIK) therapy for treatment of acute myocardial infarction: an overview of randomized placebo controlled trials. Circulation 1997;96:1152–6
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001;12(Suppl 1):S8–S11
   PubMedGoogle Scholar
• Kantor PF, Luvien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 2-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580–8
   PubMed Web of Science ®Google Scholar
• Dalla Volta S, Maraglino G, Della Valentina P et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind crossover study. Cardiovasc Drugs Ther 1990;4:853–9
   PubMed Web of Science ®Google Scholar
• Detry JM, Sellier P, PennaLorte S et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279–88
   PubMed Web of Science ®Google Scholar
• Michaelides AP. Antianginal efficacy of the combination of trimetazidine–propranolol compared with isosorbide dinitrate–propranolol in patients with stable angina. Clin Drug Invest 1997;13:8–14
   Web of Science ®Google Scholar
• Manchanda SC. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997;78:353–7
   PubMed Web of Science ®Google Scholar
• Fabiani JN, Ponzio O, Emerit I et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992;33:486–91
   PubMed Web of Science ®Google Scholar
• Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992;13:1109–15
   PubMed Web of Science ®Google Scholar
• Steg PG, Grollier G, Gallay P et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001;77:263–73
   PubMed Web of Science ®Google Scholar
• Szwed H, Pachocki R, Domnzal-Bochenska M et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drugs Ther 1999;13:215–20
   Google Scholar